Top Markets
Coin of the day
Talaris Therapeutics, Inc. Talaris Therapeutics, Inc.

Talaris Therapeutics, Inc.

TALS
Classifica tra le azioni #21258
Talaris Therapeutics, Inc. is a cell therapy company operating in the United... Talaris Therapeutics, Inc. is a cell therapy company operating in the United States, currently in its late clinical development stages. Its mission involves pioneering an allogeneic hematopoietic stem cell transplantation strategy designed to revolutionize treatment paradigms for solid organ transplantation, severe autoimmune conditions, and significant non-malignant blood, immune, and metabolic disorders. The company's flagship product, FCR001, is an innovative allogeneic cell therapy presently in Phase II clinical trials for patients undergoing living donor kidney transplantation. Beyond this, Talaris Therapeutics is actively advancing FCR002 for use in deceased donor kidney transplants, investigating FCR001 for individuals with a severe form of scleroderma, and exploring its applicability for a range of other serious non-malignant blood, immune, or metabolic conditions. Founded in 1988, the company maintains its headquarters in Louisville, Kentucky.
Prezzo delle azioni
$2.72
Ultima sincronizzazione: 2023-10-19
Capitalizzazione di mercato
$111.47M
Variazione (1 giorno)
-0.73%
Variazione (1 anno)
0.00%
Paese
US
Scambia Talaris Therapeutics, Inc. (TALS)

Categoria

Storico del prezzo dell'azione per Talaris Therapeutics, Inc. (TALS)
Prezzo di chiusura più alto: $2.72 il 2023-10-01

Prezzo di chiusura più basso: $13.89 il 2021-05-01
Storico del prezzo dell'azione di Talaris Therapeutics, Inc. dal 2021 al 2026
Andamento annuale del prezzo dell'azione
Anno Performance
2023 124.21%
2022 -91.51%
2021 0.00%
Prezzo dell'azione per aziende simili o concorrenti
Azienda Prezzo dell'azione Variazione 1a% Il paese
$547.71 38.62%
US
$1.04K 58.06%
NL
$145.75 437.43%
US
$118.70 -15.60%
AU
$770.19 8.98%
CH